|
|
|
02.04.26 - 13:06
|
Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire EN)
|
|
|
FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company's common stock with an exercise price of $6.39, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on April 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on April 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing...
|
|
|
|
|
09.03.26 - 11:06
|
Belgravia Hartford provides corporate update (PR Newswire)
|
|
|
TORONTO, March 9, 2026 /PRNewswire/ - Belgravia Hartford Capital Inc. (CSE: BLGV) (OTC: BLGVF) (FRA: ECA) ("Belgravia" or the "Company" is pleased to provide an update on its litigation with PolyNatura Corp. ("PolyNatura"), a portfolio company of Cartesian Capital Group, seeking to......
|
|
|
|
|
|
|
03.02.26 - 13:09
|
Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire EN)
|
|
|
FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company's common stock with an exercise price of $6.79, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on February 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on February 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq List...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.01.26 - 13:09
|
Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire EN)
|
|
|
FREDERICK, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On January 2, 2026, the Company issued to these employees options to purchase an aggregate of 7,350 shares of the Company's common stock with an exercise price of $6.76, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The options vest as to 25% on January 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on January 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing ...
|
|
|
18.12.25 - 22:09
|
Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors (GlobeNewswire EN)
|
|
|
FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technology Committee of the Board....
|
|
|
|
|
|
|
|
|
|
|
30.10.25 - 12:09
|
Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire EN)
|
|
|
FREDERICK, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On October 27, 2025, the Company issued to one employee an option to purchase an aggregate of 50,000 shares of the Company's common stock with an exercise price of $8.85, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. On October 29, 2025, the Company issued to another employee an option to purchase an aggregate of 2,650 shares of the Company's common stock with an exercise price of $8.20, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company's board of directors. The f...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
